alk1

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1 3 compared to other inhibitors.

ML347 (LDN 193719)(DN193719) is a highly specific ALK1 2 inhibitor ( IC50: 46 32 nM), and the selectivity for ALK2 is >300-fold than ALK3.

Compound 4, known as GALK1-IN-1, is a potent inhibitor of galactokinase, exhibiting an IC50 value of 4.2129 μM [1].

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

LDN193189 (LDN-193189) (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8 0.8 5.3 16.7 nM for ALK1 2 3 6).

LDN-193189 HCl (LDN193189 Hydrochloride) is a selective BMP type I receptor kinases inhibitor.

Vactosertib (EW-7197) is an orally bioavailable inhibitor of the serine threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity.

MU1700, an orally active and potent inhibitor targeting ALK1 2, exhibits IC50 values of 13 nM for ALK1 and 6 nM for ALK2. It demonstrates both cell membrane and high brain permeability.

Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).

LDN-214117 is a potent and selective ALK2 inhibitor.

M4K2234 (compound 26b), an ALK2 inhibitor, demonstrates selective inhibition of ALK2 and ALK5 with IC50 values of 5 nM and 2144 nM, respectively. Serving as a chemical probe for ALK1 and ALK2 protein kinases, M4K2234 holds potential for cancer research applications [1].

P7170 is an anti-cancer agent active as an mTORC1 C2 and activin receptor-like kinase 1 (ALK1) inhibitor.

K 02288 is a novel small molecule inhibitor of ALK1 2 3 6.

LDN-193189 2HCl (DM-3189 2HCl) is a selective BMP signaling inhibitor that inhibits ALK1,ALK2,ALK3 and ALK6, showing IC50s of 0.8 nM, 0.8 nM, 5.3 nM, and 16.7 nM, respectively, in kinase assays.LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively. LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors ALK2 and ALK3 in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively, and was 200-fold more selective for BMP than for TGF-β.

AZ 12799734 is an orally active, selective and potent dual inhibitor of TGFBR1 and ALK5 with inhibitory effects on BMP and TGFβ for the study of tumours.